Cargando…

Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study

Haploidentical hematopoietic stem cell transplant (haplo-HSCT) using posttransplant cyclophosphamide (PTCy) is appropriate for those who lack matched donors. Most studies using PTCy have been retrospective making conclusions difficult. ANZHIT-1 was a phase 2 study conducted at 6 Australian allogenei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moore, John, Hamad, Nada, Gottlieb, David, Bajel, Ashish, Ritchie, David, Yeung, David, Greenwood, Matthew, Purtill, Duncan, Tran, Steven, Solterbeck, Annie, Aarons, Donna, Kwan, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514140/ https://www.ncbi.nlm.nih.gov/pubmed/37467011 http://dx.doi.org/10.1182/bloodadvances.2023009840

Ejemplares similares

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022)

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders
por: Merli, Pietro, et al.
Publicado: (2022)

An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL
por: Greenwood, Matthew, et al.
Publicado: (2021)

Variable CD34(+) recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic
por: Purtill, Duncan, et al.
Publicado: (2020)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
por: Teh, Charis E., et al.
Publicado: (2022)

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
por: Johnsrud, Andrew, et al.
Publicado: (2021)

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
por: Belada, David, et al.
Publicado: (2023)

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
por: Mascarenhas, John, et al.
Publicado: (2022)

Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors
por: Miller, Eric J., et al.
Publicado: (2022)

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
por: de Botton, Stéphane, et al.
Publicado: (2022)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

Higher rate of progression in HIV(–) than in HIV(+) patients after rituximab for HHV8(+) multicentric Castleman disease
por: Rasmussen, Camille, et al.
Publicado: (2023)

Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival
por: Martinez, Caridad, et al.
Publicado: (2022)

Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant
por: Chung, David J., et al.
Publicado: (2022)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT
por: Kinoshita, Hannah, et al.
Publicado: (2022)

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
por: Epperla, Narendranath, et al.
Publicado: (2022)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
por: Martin, Peter, et al.
Publicado: (2022)

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
por: Shimony, Shai, et al.
Publicado: (2023)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
por: Hamilton, Betty K., et al.
Publicado: (2023)

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
por: Elsawy, Mahmoud, et al.
Publicado: (2022)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma
por: Olszewski, Adam J., et al.
Publicado: (2021)

Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI
por: Khorana, Alok A., et al.
Publicado: (2022)

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2023)

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial
por: Woller, Scott C., et al.
Publicado: (2022)

Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up
por: Röth, Alexander, et al.
Publicado: (2023)

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
por: Kwiatkowski, Janet L., et al.
Publicado: (2022)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
por: Davids, Matthew S., et al.
Publicado: (2021)

Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria
por: Henrici, Ryan C., et al.
Publicado: (2021)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2tt31tm7d9p9p8jijdtuk018e9